# Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma

> **NCT03410693** · PHASE2,PHASE3 · COMPLETED · sponsor: **Bayer** · enrollment: 175 (actual)

## Conditions studied

- Carcinoma, Transitional Cell

## Interventions

- **DRUG:** Rogaratinib (BAY1163877)
- **DRUG:** Chemotherapy

## Key facts

- **NCT ID:** NCT03410693
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-31
- **Primary completion:** 2020-10-27
- **Final completion:** 2020-10-27
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2022-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03410693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03410693, "Study of Rogaratinib (BAY1163877) vs Chemotherapy in Patients With FGFR (Fibroblast Growth Factor Receptor)-Positive Locally Advanced or Metastatic Urothelial Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03410693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*